Ambrx Biopharma Inc(NASDAQ:AMAM) 
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system.
Website: https://ambrx.com/
Founded: 2003
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2023-06-30 | 2023-03-31 | 2022-12-31 |
|---|---|---|---|
revenues | 1,123,000 | 24,000 | |
operating expenses: | |||
research and development | 14,393,000 | 9,750,000 | |
general and administrative | 5,900,000 | 6,306,000 | |
impairment of intangible assets | |||
total operating expenses | 20,293,000 | 16,056,000 | |
income from operations | -19,170,000 | -16,032,000 | |
yoy | |||
qoq | 19.57% | ||
other income, net: | |||
investment income | 1,428,000 | 551,000 | |
interest income | 211,000 | 190,000 | |
other income | 10,000 | 62,000 | |
total other income | 1,649,000 | 803,000 | |
income before income taxes | -17,521,000 | -15,229,000 | |
benefit from income taxes | -305,000 | -73,000 | |
net income | -17,826,000 | -15,302,000 | |
yoy | |||
qoq | 16.49% | ||
net income per share | -0.05 | -0.05 | |
weighted-average ordinary shares used to compute net income per share—basic and diluted | 391,283,214 | ||
other comprehensive loss, net of tax: | |||
other comprehensive income, net of tax: | |||
changes in comprehensive income before reclassifications | -13 | -26 | |
amounts reclassified from accumulated other comprehensive loss | 36 | 352 | |
total other comprehensive income | 23 | 326 | |
comprehensive loss | -17,803 | -14,976 | |
weighted-average ordinary shares used to compute net income per share —basic and diluted | 314,969,897 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2023-06-30 | 2023-03-31 | 2022-12-31 |
|---|---|---|---|
assets | |||
current assets: | |||
cash and cash equivalents | 228,265,000 | 149,584,000 | 55,610,000 |
restricted cash | 665,000 | 665,000 | 831,000 |
marketable debt securities, available-for-sale | 6,824,000 | 7,940,000 | 28,873,000 |
accounts receivable | 81,000 | 62,000 | 376,000 |
prepaid expenses and other current assets | 5,578,000 | 4,691,000 | 4,893,000 |
total current assets | 241,413,000 | 162,942,000 | 90,583,000 |
marketable debt securities, available-for-sale, net of current portion | 8,798,000 | 16,793,000 | |
property and equipment | 3,195,000 | 2,889,000 | 3,044,000 |
right-of-use assets | 10,044,000 | 10,511,000 | 10,968,000 |
intangible assets | 24,935,000 | 25,093,000 | 25,250,000 |
other long-term assets | 357,000 | 380,000 | 339,000 |
total assets | 279,944,000 | 210,613,000 | 146,977,000 |
liabilities and shareholders' equity | |||
current liabilities: | |||
accounts payable | 6,362,000 | 7,107,000 | 3,205,000 |
accrued liabilities | 9,556,000 | 6,782,000 | 11,314,000 |
operating lease liabilities, current portion | 1,854,000 | 1,793,000 | 1,734,000 |
deferred revenue, current portion | 407,000 | 407,000 | 407,000 |
total current liabilities | 18,179,000 | 16,089,000 | 16,660,000 |
operating lease liabilities, net of current portion | 9,163,000 | 9,710,000 | 10,245,000 |
deferred tax liabilities | 880,000 | 880,000 | 880,000 |
deferred revenue, net of current portion | 1,342,000 | 1,342,000 | 1,342,000 |
total liabilities | 29,564,000 | 28,021,000 | 29,127,000 |
commitments and contingencies | |||
shareholders' equity | |||
ordinary shares, par value 0.0001... | 43,000 | 39,000 | 27,000 |
additional paid-in capital | 576,046,000 | 490,459,000 | 410,753,000 |
accumulated other comprehensive loss | -953,000 | -976,000 | -1,302,000 |
accumulated deficit | -324,756,000 | -306,930,000 | -291,628,000 |
total shareholders' equity | 250,380,000 | 182,592,000 | 117,850,000 |
total liabilities and shareholders' equity | 279,944,000 | 210,613,000 | 146,977,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2023-06-30 | 2023-03-31 |
|---|---|---|
cash flows from operating activities: | ||
net income | -17,826,000 | -15,302,000 |
noncash adjustments reconciling net income to net cash from operating activities: | ||
loss on impairment of intangible assets | ||
share-based compensation expense | 2,886,000 | 1,938,000 |
noncash lease expense | 654,000 | 712,000 |
depreciation and amortization | 210,000 | 208,000 |
amortization of intangible assets | 158,000 | 157,000 |
accretion/amortization of investment securities | -27,000 | -299,000 |
loss on disposal of property and equipment | 1,000 | |
changes in operating assets and liabilities: | ||
accounts receivable | -19,000 | 314,000 |
prepaid and other current assets and other long-term assets | -864,000 | 159,000 |
accounts payable | -732,000 | 3,886,000 |
accrued liabilities | 3,084,000 | -4,010,000 |
deferred revenue | ||
operating lease liabilities | -673,000 | -731,000 |
net cash from operating activities | -13,150,000 | -12,967,000 |
capital expenditures | 0 | |
free cash flows | -13,150,000 | |
cash flows from investing activities: | ||
purchases of marketable debt securities, available-for-sale | 0 | -40,645,000 |
sales of marketable debt securities, available-for-sale | 3,464,000 | 50,799,000 |
maturities of marketable debt securities, available-for-sale | 6,500,000 | 19,400,000 |
purchases of property and equipment | ||
net cash from investing activities | 9,181,000 | 29,554,000 |
cash flows from financing activities: | ||
proceeds from short-term bridge loan | ||
repayment of short-term bridge loan | ||
payments of directors and officers insurance premium financing agreement | -373,000 | -559,000 |
proceeds from issuance of common stock for cash, net of issuance costs | ||
issuance of ordinary shares for cash through registered direct offering with a related party, net of issuance costs | ||
issuance of ordinary shares for cash pursuant to employee stock purchase programs | ||
payments of costs for the issuance of ordinary shares | ||
net cash from financing activities | 82,650,000 | 77,221,000 |
net increase in cash, cash equivalents and restricted cash | 78,681,000 | 93,808,000 |
cash, cash equivalents and restricted cash, beginning of period | 0 | 56,441,000 |
cash, cash equivalents and restricted cash, end of period | 78,681,000 | 150,249,000 |
supplemental information: | ||
cash paid for interest | ||
cash paid for income taxes | ||
noncash investment and financing activities: | ||
property and equipment costs in accounts payable and accrued liabilities | -268,000 | 545,000 |
direct offering costs in accounts payable and accrued liabilities | ||
unsettled trade of marketable debt securities, available-for-sale | ||
proceeds from issuance of ordinary shares, net of issuance costs | 77,780,000 | |
noncash adjustments reconciling net income to cash flows from operating activities: | ||
change in fair value of redeemable noncontrolling interests | ||
acquisition of intangible assets | ||
proceeds from directors and officers insurance premium financing agreement | ||
payments to acquire the ambrx shanghai noncontrolling interests | ||
payments of costs for the issuance of series b preferred shares | ||
effect of exchange rate changes on cash, cash equivalents and restricted cash | ||
rou assets and lease liabilities obtain through reassessment of an existing lease | ||
conversion of convertible preferred shares into ordinary shares | ||
reclassification of redeemable noncontrolling interests from temporary equity to current liabilities | ||
accretion of redeemable noncontrolling interests to fair value | ||
deferred initial public offering costs in accounts payable and accrued liabilities | ||
reclassification of accumulated other comprehensive loss upon settlement of redeemable noncontrolling interests |